Clinical Trial ResultsImmutep reported positive response data from the ongoing P1 INSIGHT-003 study evaluating the triple combination of eftilagimod + chemotherapy + Keytruda in 1L metastatic non-small cell lung cancer, demonstrating a 60.8% overall response rate and 90.2% disease control rate.
Financial PositionThe company has a strong cash position, expecting to be funded through the end of 2026.
Regulatory ProgressImmutep has requested a meeting with the FDA to discuss the path forward, indicating progress in regulatory engagement.